Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

BioVaxys Technology Corp C.BIOV

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.

Latest News

BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio


BioVaxys Further Expands Vaccines Intellectual Property Portfolio


BIOVAXYS CLOSES FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT


BioVaxys Announces New Chief Financial Officer


BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in...


BioVaxys Technology Corp. (CSE:BIOV) closes firs tranche of non-brokered private placement


BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT


BIOVAXYS ANNOUNCES WARRANT EXTENSION


BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT


BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT


BIOVAXYS ANNOUNCES PROPOSED DEBT SETTLEMENT


Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys...


Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU...


BioVaxys (CSE:BIOV) reports progress on a universal SARS vaccine


BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program